FTC Sues to Block Covetrus's $3.5 Billion Purchase of MWI Veterinary Supply
On November 13, 2026, the Federal Trade Commission sued to block Covetrus Inc. from acquiring rival distributor MWI Veterinary Supply Inc. for $3.5 billion from its parent company, Cencora Inc. Covetrus is owned by private equity firms Clayton, Dubilier & Rice LLC and TPG Inc. The FTC voted 2-0 to file a lawsuit seeking a permanent injunction in the U.S. District Court for the Southern District of New York, alongside attorneys general from 13 states. According to the FTC, Covetrus and MWI are the two largest distributors of veterinary products in the United States, selling pharmaceuticals, vaccines, surgical tools, and everyday supplies to independent clinics and large corporate practices. The agency warns that combining these two fierce competitors would eliminate a long-running price war between them. For pet owners and veterinary clinics, the FTC says this deal would lead to higher costs, worse service quality, and reduced competition across the nation's veterinary supply market.
What was announced
The Federal Trade Commission filed a lawsuit to block the proposed $3.5 billion acquisition of MWI Veterinary Supply Inc. by Covetrus Inc. Covetrus and its owners, Clayton, Dubilier & Rice LLC and TPG Inc., planned to buy MWI from Cencora Inc.
The agency voted 2-0 to request a permanent injunction against the deal. Filed in the U.S. District Court for the Southern District of New York, the complaint includes 13 state attorneys general as co-plaintiffs from Arizona, Arkansas, California, Colorado, Maine, Michigan, Minnesota, Nebraska, New York, North Carolina, Ohio, Oregon, and Texas.
What it means
Covetrus and MWI are the two largest distributors serving U.S. veterinary clinics and large corporate veterinary accounts. They distribute items like vaccines, pharmaceuticals, surgical goods, and gloves. Both companies operate national networks of distribution centers that allow quick delivery and bulk pricing discounts.
The FTC stated that these two companies currently engage in direct competition and an ongoing price war. For instance, Covetrus lowered its prices and created rebates through its VetSuite program in response to MWI's pricing tactics. Online comparison platforms like Vetcove have allowed clinics to compare prices and push for better terms from both distributors.
If the companies merge, the FTC states the deal would create highly concentrated markets that break federal antitrust guidelines. Small independent clinics, large corporate practices, and pet owners would face higher prices and degraded service quality. The agency argues that smaller specialty distributors or direct product manufacturers cannot adequately replace the competition that MWI and Covetrus currently provide.
What the announcement does not tell us
The FTC announcement does not provide a timetable for court proceedings or state when the U.S. District Court will hear the case. It also does not state whether Covetrus, TPG, Clayton, Dubilier & Rice, or Cencora plan to challenge the suit or propose remedies. Additionally, the document does not estimate specific dollar amounts for expected price increases if the transaction proceeds.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is US FTC Press Releases’s own. Always check the original before acting on anything here.
FTC alleges that combining the two biggest distributors of veterinary products and services will drive up costs and lead to higher prices for veterinary clinics and pet owners The Federal Trade Commission sued today to block Covetrus Inc. and its owners, Clayton, Dubilier & Rice LLC and TPG Inc., from acquiring its closest competitor, MWI Veterinary Supply Inc., for $3.5 billion from MWI’s parent, Cencora Inc. View Press Release
Opens www.ftc.gov
More from US FTC Press Releases
This content is for informational purposes only and is not professional advice. Specifications, prices, plan tiers, and features change frequently and may differ from what is shown here; verify current details on the manufacturer's or company's official page before purchasing. Ratings are based on analysis of published documentation, not independent lab testing.